ABL1 is altered in 0.89% of malignant salivary gland neoplasm patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is altered in 2.08% of malignant salivary gland neoplasm patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ALK status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is altered in 1.55% of malignant salivary gland neoplasm patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for malignant salivary gland neoplasm, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and malignant salivary gland neoplasm as inclusion criteria, 2 are phase 2 (2 open) [3].

DDR2 is altered in 1.16% of malignant salivary gland neoplasm patients [2].

DDR2 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is altered in 0.98% of malignant salivary gland neoplasm patients [2].

EGFR is an inclusion eligibility criterion in 2 clinical trials for malignant salivary gland neoplasm, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and malignant salivary gland neoplasm as inclusion criteria, 2 are phase 2 (2 open) [3].

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 6.96% of malignant salivary gland neoplasm patients [2].

ERBB2 is an inclusion eligibility criterion in 3 clinical trials for malignant salivary gland neoplasm, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant salivary gland neoplasm as inclusion criteria, 3 are phase 2 (3 open) [3].

Ado-trastuzumab emtansine, pertuzumab, and trastuzumab have evidence of efficacy in patients with ERBB2 mutation in malignant salivary gland neoplasm [3].

ERBB4 is altered in 0.88% of malignant salivary gland neoplasm patients [2].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is altered in 1.36% of malignant salivary gland neoplasm patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is altered in 1.29% of malignant salivary gland neoplasm patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is altered in 0.69% of malignant salivary gland neoplasm patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is altered in 1.62% of malignant salivary gland neoplasm patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FRK status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR is altered in 1.78% of malignant salivary gland neoplasm patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KDR status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is altered in 2.04% of malignant salivary gland neoplasm patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 2.17% of malignant salivary gland neoplasm patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is altered in 1.25% of malignant salivary gland neoplasm patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 1.11% of malignant salivary gland neoplasm patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PTCH1 is altered in 1.24% of malignant salivary gland neoplasm patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is altered in 0.71% of malignant salivary gland neoplasm patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is altered in 1.12% of malignant salivary gland neoplasm patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

SMO is altered in 0.73% of malignant salivary gland neoplasm patients [2].

SMO is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMO status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TEK is altered in 1.25% of malignant salivary gland neoplasm patients [2].

TEK is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TEK status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA is altered in 0.78% of malignant salivary gland neoplasm patients [2].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].